|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gut microbiota imbalance and colorectal cancer显示文摘The gut microbiota acts as a real organ. The symbiotic interactions between resident micro-organisms and the digestive tract highly contribute to maintain the gut homeostasis. However, alterations to the microbiome caused by environmental changes(e.g., infection, diet and/or lifestyle) can disturb this symbiotic relationship and promote disease, such as inflammatory bowel diseases and cancer. Colorectal cancer is a complex association of tumoral cells, non-neoplastic cells and a large amount of micro-organisms, and the involvement of the microbiota in colorectal carcinogenesis is becoming increasingly clear. Indeed, many changes in the bacterial composition of the gut microbiota have been reported in colorectal cancer, suggesting a major role of dysbiosis in colorectal carcinogenesis. Some bacterial species have been identified and suspected to play a role in colorectal carcinogenesis, such as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, Enterococcus faecalis, Clostridium septicum, Fusobacterium spp. and Escherichia coli. The potential pro-carcinogenic effects of these bacteria are now better understood. In this review, we discuss the possible links between the bacterial microbiota and colorectal carcinogenesis, focusing on dysbiosis and the potential pro-carcinogenic properties of bacteria, such as genotoxicity and other virulence factors, inflammation, host defenses modulation, bacterial derived metabolism, oxidative stress and anti-oxidative defenses modulation. We lastly describe how bacterial microbiota modifications could represent novel prognosis markers and/or targets for innovative therapeutic strategies. | Johan Gagnière Jennifer Raisch Julie Veziant Nicolas Barnich Richard Bonnet Emmanuel Buc Marie-Agnès Bringer Denis Pezet Mathilde Bonnet | 2016 | World Journal of Gastroenterology2016，22，2： | 76 |
| 2 | Ablation techniques for primary and metastatic liver tumors显示文摘Ablative treatment methods have emerged as safe and effective therapies for patients with primary and secondary liver tumors who are not surgical candidates at the time of diagnosis.This article reviews the current literature and describes the techniques,complications and results for radiofrequency ablation,microwave ablation,cryoablation,and irreversible electroporation. | Michael J Ryan Jonathon Willatt Bill S Majdalany Ania Z Kielar Suzanne Chong Julie A Ruma Amit Pandya | 2016 | World Journal of Hepatology2016，8，3： | 13 |
| 3 | Microbial markers in colorectal cancer detection and/or prognosis显示文摘Colorectal cancer(CRC) is the second leading cause of cancer worldwide. CRC is still associated with a poor prognosis among patients with advanced disease. On the contrary, due to its slow progression from detectable precancerous lesions, the prognosis for patients with early stages of CRC is encouraging. While most robust methods are invasive and costly, actual patient-friendly screening methods for CRC suffer of lack of sensitivity and specificity. Therefore, the development of sensitive, non-invasive and cost-effective methods for CRC detection and prognosis are necessary for increasing the chances of a cure. Beyond its beneficial functions for the host, increasing evidence suggests that the intestinal microbiota is a key factor associated with carcinogenesis. Many clinical studies have reported a disruption in the gut microbiota balance and an alteration in the faecal metabolome of CRC patients, suggesting the potential use of a microbialbased test as a non-invasive diagnostic and/or prognostic tool for CRC screening. This review aims to discuss the microbial signatures associated with CRC known to date, including dysbiosis and faecal metabolome alterations, andthe potential use of microbial variation markers for noninvasive early diagnosis and/or prognostic assessment of CRC and advanced adenomas. We will finally discuss the possible use of these markers as predicators for treatment response and their limitations. | Romain Villéger Amélie Lopès Julie Veziant Johan Gagnière Nicolas Barnich Elisabeth Billard Delphine Boucher Mathilde Bonnet | 2018 | World Journal of Gastroenterology2018，24，22： | 10 |
| 4 | Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer显示文摘Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease,resulting in increased local drug concentrations.Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy.The patient was treated with a combination of gemcitabine and oxaliplatin using HAI.The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI.The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed in this paper.HAI of gemcitabine-oxaliplatin should be evaluated in further clinical trials. | Boris Guiu Julie Vincent Séverine Guiu Sylvain Ladoire Pablo Ortega-Deballon Jean-Pierre Cercueil Bruno Chauffert Franois Ghiringhelli | 2010 | World Journal of Gastroenterology2010，16，9： | 4 |
| 5 | Radiation-induced intestinal inflammation显示文摘Radiation induces an important inflammatory response in the irradiated organs, characterized by leukocyte infiltration and vascular changes that are the main limiting factor in the application of this therapeutic modality for the treatment of cancer. Recently, a considerable investigative effort has been directed at determining the molecular mechanisms by which radiation induces leukocyte recruitment, in order to create strategies to prevent intestinal inflammatory damage. In these review, we consider current available evidence on the factors governing the process of leukocyte recruitment in irradiated organs, mainly derived from experimental studies, with special attention to adhesion molecules, and their value as therapeutic targets. | Meritxell Mollà Julián Panés | 2007 | World Journal of Gastroenterology2007，13，22： | 4 |
| 6 | Are we giving biologics too late? The case for early versus late use显示文摘Corticosteroids and immunomodulators have been the mainstay therapies for Crohn’s disease. Corticosteroids are highly effective to control symptoms in the short- term, but they are not effective in maintaining remission, they heal the mucosa in a reduced proportion of cases, and long-time exposure is associated with an increased risk of infections and mortality. Immunomodulators, azathioprine and methotrexate, heal the mucosa in a higher proportion of patients that corticosteroids but their onset of action is slow and they benefit less than half of patients with Crohn’s disease. In the last decade, medical therapy for Crohn’s disease has experienced a remarkable change due to the introduction of biologic therapy, and particularly the use of anti-tumour necrosis factor-alpha agents. Infliximab, adalimumab, and certolizumab pegol have demonstrated efficacy for induction and maintenance of remission in active Crohn’s disease. These agents have raised the bar for what is a suitable symptomatic response in Crohn’s disease and modification of the natural history of the disease has become a major goal in the treatment of Crohn’s disease. There are several data in the literature that suggest that early use of biologic therapy and achievement of mucosal healing contribute to disease course modification. However, many questions on early biological therapy for Crohn’s disease remain still unanswered. | Elena Ricart Orlando García-Bosch Ingrid Ordás Julián Panés | 2008 | World Journal of Gastroenterology2008，14，36： | 4 |
| 7 | Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data显示文摘AIM To investigate the relationship between 25-hydroxyvitamin D [25(OH)D] levels and fibrosis stage in patients with non-alcoholic fatty liver disease(NAFLD).METHODS Two individual reviewers identified relevant studies using the Pub Med, EMBASE, Cochrane, and Scopus databases. Inclusion criteria were as follows:(1) Studies that evaluated adults with NAFLD and serum or plasma 25(OH)D levels; and(2) assessed fibrosis stage using liver biopsy. A rigorous analysis yielded six articles as having sufficient data to employ in evaluating the association of serum vitamin D levels in patients with NAFLD based on their liver fibrosis stage by histopathological analysis. The lead investigators of each of the six studies were contacted and the data were collected. To meta-analyze vitamin D levels in F0-F2 vs F3-F4 fibrosis, a random-effects meta-analysis fit using restricted maximum likelihood was applied. To examine trends across each stage of fibrosis with respect to vitamin D levels, a meta-regression was performed. P < 0.05 was considered statistically significant. RESULTS A total of 937 subjects from six studies were included in the final analysis to evaluate the association of serum vitamin D levels in patients with NAFLD based on their liver fibrosis stage by histopathological analysis. The lead investigators of each of the six studies were contacted and the data were collected. First, the investigators performed a meta-analysis to compare serum vitamin D levels in patients with NAFLD with stage F0-F2 compared to F3-F4, which did not show significance [meta-estimate of the pooled mean difference =-0.86, P = 0.08(-4.17, 2.46)]. A metaregression evaluation of serum vitamin 25(OH)D levels across the individual stages(F0-F4) of fibrosis did not show an association for the six included studies.CONCLUSION Low vitamin D status is not associated with higher stages of liver fibrosis in patients with NAFLD. | Behnam Saberi Alia S Dadabhai Julie Nanavati Lin Wang Russell T Shinohara Gerard E Mullin | 2018 | World Journal of Hepatology2018，10，1： | 3 |
| 8 | The importance of avoiding unnecessary right ventricular pacing in clinical practice显示文摘Symptomatic bradycardia is effectively treated with the implantation of a cardiac pacemaker. Although a highly successful therapy, during recent years there has been a focus on the negative effects associated with longterm pacing of the apex of the right ventricle(RV). It has been shown in both experimental and clinical studies that RV pacing leads to ventricular dyssynchrony, similar to that of left bundle branch block, with subsequent detrimental effects on cardiac structure and function, and in some cases adverse clinical outcomes such as atrial fibrillation, heart failure and death. There is substantial evidence that patients with reduced left ventricular function(LVEF) are at particular high risk of suffering the detrimental clinical effects of long-term RV pacing. The evidence is, however, incomplete, coming largely from subanalyses of pacemaker and implantable cardiac defibrillator studies. In this group of patients with reduced LVEF and an expected high amount of RV pacing, biventricular pacing(cardiac resynchronization therapy) devices can prevent the negative effects of RV pacing and reduce ventricular dyssynchrony. Therefore, cardiac resynchronization therapy has emerged as an attractive option with promising results and more clinical studies are underway. Furthermore, specific pacemaker algorithms, which minimize RV pacing, can also reduce the negative effects of RV stimulation on cardiac function and may prevent clinical deterioration. | Finn Akerstrm Miguel A Arias Marta Pachón Jesús Jiménez-López Alberto Puchol Justo Juliá-Calvo | 2013 | World Journal of Cardiology2013，5，11： | 3 |
| 9 | Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis显示文摘 | Javier Fernández Miquel Navasa Juliá Gómez Jordi Colmenero Jordi Vila Vicente Arroyo Juan Rodés | 2002 | Hepatology2002，，1： | 3 |
| 10 | Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn’s Disease显示文摘 | Ingrid Ordás Jordi Rimola Sonia Rodríguez José M. Paredes María J. Martínez-Pérez Esther Blanc Juan A. Arévalo Marta Aduna Montserrat Andreu Alexander Radosevic Anna M. Ramírez-Morros Susana Pinó Marta Gallego Aranzazu Jauregui-Amezaga Elena Ricart Julián | 2013 | Gastroenterology2013，，： | 3 |
| 11 | Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study显示文摘瞄准:与活跃类固醇依赖者 ulcerative 在病人与 10 个 granulocyteaphaeresis 会议相比评估 5 的功效。方法:在这名飞行员,未来,多集中使随机化的试用,有中等活跃的类固醇的 20 个病人 -- 依赖 ulcerative 被使随机化到 5 或 10 个 granulocyteaphaeresis 会议。主要目的是在 wk 的临床的宽恕 17。第二等的措施包括了内视镜的宽恕和类固醇消费。结果:九个病人被使随机化到 5 个 granulocyteaphaeresis 会议(组 1 ) 和 11 个病人到 10 个 granulocyteaphaeresis 会议(组 2 ) 。在 wk 17,在在组 2 的组 1 病人和 45.45% 的 37.5% 病人在临床的宽恕。临床的宽恕被内视镜的宽恕在所有情况中伴随。完成宽恕的百分之 86 个病人在 wk 是没有类固醇的 17。每日的类固醇要求在组 2 是显著地更低的。病人的 89% 在一年后续期间留在宽恕。一个严肃的不利事件不与学习治疗有关,被报导。结论:Granulocyteaphaeresis 为类固醇依赖者 ulcerative 的治疗安全、有效。在这张人口,增加 aphaeresis 会议的数字没与更高的宽恕率被联系,但是负担得起重要类固醇圆材效果。 | Elena Ricart Maria Esteve Montserrat Andreu Francesc Casellas David Monfort Miquel Sans Natalia Oudovenko Raúl Lafuente Julián Panés | 2007 | World Journal of Gastroenterology2007，13，15： | 3 |
| 12 | Arterial Stiffness Is Regulated by Nitric Oxide and Endothelium-Derived Hyperpolarizing Factor During Changes in Blood Flow in Humans显示文摘 | Jeremy Bellien Julie Favre Michele Iacob Ji Gao Christian Thuillez Vincent Richard Robinson Joannidès | 2010 | Hypertension2010，，3： | 2 |
| 13 | Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening显示文摘 | Aranzazu Jauregui-Amezaga Fanny Turon Ingrid Ordás Marta Gallego Faust Feu Elena Ricart Julián Panés | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
| 14 | Electronic remote blood issue:a combination of remote blood issue with a system for end-to-end electronic control of transfusion to provide a 'total solution' for a safe and timely hospital blood transfusion service 显示文摘 | Julie S Amanda D Jonathan K | 2008 | Transfusion2008，，： | 1 |
| 15 | High yield production of a human therapeutic protein in tobacco chloroplasts 显示文摘 | Jeffery M S Bradley G Julie G | 2000 | Natl Biotechn2000，18，： | 1 |
| 16 | Mediation of transforming growth factor-β1 -stimulated matrix contraction by fibroblasts 显示文摘 | Julie T Gregory S Timothy D | 2003 | Am J Pathol2003，163，： | 1 |
| 17 | Suppression and recovery of estrous behavior in Syrian hamsters after changes in metabolic fuel availability显示文摘 | Juli E Jones Laura S Lubbers | 2001 | Am J Physiol Regulatory Integrative Comp Physiol2001，280，： | 1 |
| 18 | The nonmanufacturing patent owner: toward a theory of efficient infringement 显示文摘 | JULIE S TURNERT | 1998 | California Law Review1998，，86： | 1 |
| 19 | Automatic TOBI prediction and alignment to speed manual labeling of prosody显示文摘 | ANNK S JULIA H JULIE M | 2001 | Speech communication2001，33，： | 1 |
| 20 | Plasminogen activator inhibitor 1 and turnout growth, invasion, and metastasis 显示文摘 | Michelle KV Durand Julie S Bdker Armi Christensen | 2004 | Thromb Haemost2004，91，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员